| Name | Title | Contact Details |
|---|
Clearway Health partners with hospitals and health systems to build or strengthen their own specialty pharmacy program, improve access to care and provide personalized support to vulnerable patients, families, providers and care managers to eliminate b...
In 2011, Viva Naturals was founded by a team of people who didn`t just know a lot about wellness—they made it their way of life. And nothing has changed since: from the reception desk to the boardroom, everyone at Viva believes in the power of healthy living (and the power of a good laugh, because it`s not healthy to take yourself too seriously). As wellness enthusiasts, we take pride in putting out the caliber of product we`d want for ourselves.
AmerisourceBergen Technology Group is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HFS Consultants is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.